EUVIMEDEUVIMED entdecken
Crossref

A New Perspective on the Effectiveness of FDG PET/CT in Predicting KRAS Mutation in Colon Cancer Cases

Fatih Tamer iD, Ulkem Yararbas

Cancer Biotherapy and Radiopharmaceuticals · 2024

DOI: 10.1089/cbr.2024.0028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2024. Verfasst von Fatih Tamer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Niğde Ömer Halisdemir University Training and Research Hospital, Niğde, Turkey. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Proto-Oncogene Proteins p21(ras), Positron Emission Tomography Computed Tomography, Colonic Neoplasms. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The main aim of this study was to evaluate the effectiveness of 18F-fluorodeoxyglucose (18FDG) positron emission tomography/computerized tomography (PET/CT) parameters in predicting the Kristen rat sarcoma viral oncogene(KRAS) mutation status of patients with colon cancer. Materials and Methods: Between April 2013 and December 2020, 79 patients who were diagnosed with colon cancer by colonoscopy underwent staging 18FDG PET/CT with this diagnosis and met all the inclusion criteria were included in this study. Clinical and prognostic features and also imaging (18FDG PET/CT and magnetic resonance imaging) reports of the patients were collected and analyzed retrospectively.

Results

KRAS mutation was seen in 32 of patients (40.5%). No significant difference was observed between KRAS mutant and wild-type patients in terms of clinical features (tumor location, findings regarding metastasis, T stage, and tumor differentiation grade in patients who underwent surgery) and overall survival. Progression-free survival was significantly shorter in KRAS mutant patients (p = 0.018). Primary tumor standardized uptake value (SUVmean) was significantly higher in KRAS mutant cases in the whole group (p = 0.024) and in patients in whom KRAS analysis was performed only in the primary lesion (p = 0.036). The cutoff value for predicting KRAS mutation status was 7.01 g/mL (area under the curve [AUC]: 0.650, confidence interval [CI] 95%, 0.56-0.74).

Conclusions

When colon and rectal cancer cases were evaluated separately, the primary tumor SUVmean value was significantly higher in KRAS mutant colon cancer cases. However, its effectiveness in predicting KRAS mutation status was low, similar to other parameters in the literature.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Proto-Oncogene Proteins p21(ras)Positron Emission Tomography Computed TomographyColonic NeoplasmsMutationRadiopharmaceuticalsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultPrognosisAged, 80 and over

Stichwörter der Autor:innen

KRASPET/CTcolon cancermutation status

Substanzen

Fluorodeoxyglucose F18Proto-Oncogene Proteins p21(ras)KRAS protein, humanRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Niğde Ömer Halisdemir University Training and Research Hospital, Niğde, Turkey.
  • Department of Nuclear Medicine, Ege University Medical Faculty, Izmir, Turkey.

ORCID-Profile: Fatih Tamer

Zitieren

APA

Tamer, F., & Yararbas, U. (2024). A New Perspective on the Effectiveness of FDG PET/CT in Predicting KRAS Mutation in Colon Cancer Cases. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2024.0028

Vancouver

Tamer F, Yararbas U. A New Perspective on the Effectiveness of FDG PET/CT in Predicting KRAS Mutation in Colon Cancer Cases. Cancer Biotherapy and Radiopharmaceuticals. 2024. doi:10.1089/cbr.2024.0028

BibTeX
@article{Tamer2024,
  author = {Tamer, Fatih and Yararbas, Ulkem},
  title = {A New Perspective on the Effectiveness of FDG PET/CT in Predicting KRAS Mutation in Colon Cancer Cases},
  journal = {Cancer Biotherapy and Radiopharmaceuticals},
  year = {2024},
  doi = {10.1089/cbr.2024.0028}
}
Kostenlos starten →